Company Description

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States.

Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

The company was founded in 2014 and is based in Paramus, New Jersey.

Polaryx Therapeutics, Inc.

Country	United States
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	Alex Yang

Contact Details

Address: South Tower, 140 E Ridgewood Avenue Paramus, New Jersey 07652 United States
Phone	201 940 7236
Website	polaryx.com

Stock Details

Ticker Symbol	PLYX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	2075320
CUSIP Number	73110F100
ISIN Number	US73110F1003
SIC Code	2834

Key Executives

Name	Position
Alex Yang J.D., L.L.M.	Chief Executive Officer and Chair of Board
G. Michael Landis CPA	Chief Financial Officer and Director
Andrew John O	Chief Investment Officer

Latest SEC Filings

Date	Type	Title
Jul 28, 2026	ARS	Filing
Jul 28, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 28, 2026	DEF 14A	Other definitive proxy statements
Jul 24, 2026	S-8	Securities to be offered to employees in employee benefit plans
Jul 21, 2026	8-K	Current Report
Jul 17, 2026	8-K	Current Report
May 28, 2026	8-K	Current Report
May 15, 2026	10-Q	Quarterly Report
Mar 24, 2026	10-K	Annual Report
Feb 5, 2026	SCHEDULE 13D	Filing

View All SEC Filings